查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1950555

注射用齊拉西酮甲磺酸鹽市場按適應症、規格、包裝、年齡層和最終用戶分類，全球預測，2026-2032年

Ziprasidone Mesylate for Injection Market by Indication, Strength, Packaging, Age Group, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，注射用齊拉西酮甲磺酸鹽市場價值將達到 13.9 億美元，到 2026 年將成長至 15.1 億美元，到 2032 年將達到 26.8 億美元，年複合成長率為 9.84%。

關鍵市場統計數據
基準年 2025 13.9億美元
預計年份：2026年 15.1億美元
預測年份 2032 26.8億美元
複合年成長率 (%) 9.84%

本文全面介紹了注射甲磺酸齊拉西酮在急性精神科治療中的臨床作用、操作限制和相關人員的優先事項。

本導言概述了注射甲磺酸齊拉西酮在急性精神疾病治療中的治療作用和臨床效用，為更深入的操作和策略分析奠定了基礎。作為一種肌注抗精神病藥物，該製劑可快速控制精神分裂症的急性躁鬱症和思覺失調症的急性躁狂發作，當口服給藥因患者躁動或依從性風險而不可行或無效時，它便能滿足臨床需求。臨床醫生依靠注射來穩定患者病情、快速鎮靜行為緊急情況，並促進患者及時過渡到長期口服治療。

臨床優先事項、供應鏈韌性和監管收緊正在重塑全球注射精神藥物模式。

注射型精神科治療領域正經歷變革性的轉變，其驅動力包括不斷發展的臨床實踐、供應鏈重組以及監管的加強。臨床醫師越來越重視起效迅速、安全性高的介入措施，以最大限度地減少對病人的約束需求，並降低急診就診量。這種臨床趨勢提升了注射型抗精神病藥物的戰略重要性，這類藥物具有起效可預測、不利事件可控以及與醫院監測通訊協定相容等優點。

2025年美國關稅對無菌注射劑供應鏈的影響：營運與採購評估

美國2025年實施的累積關稅對藥品供應鏈產生了廣泛影響，尤其對無菌注射療法影響顯著。進口原料藥和包裝材料的關稅增加了依賴國際採購的製造商的成本，促使他們即時採取戰術性措施，例如重新談判供應商合約和短期價格調整。這些措施也加速了企業多元化供應鏈網路和將關鍵生產環節遷至更靠近終端市場的策略進程。

詳細的細分分析揭示了臨床嚴重程度、最終用戶環境、配方強度、包裝和年齡層考慮因素如何相互作用，從而決定產品的使用情況。

細分市場分析揭示了臨床、採購和製劑變數如何相互作用，共同塑造注射用齊拉西酮甲磺酸鹽的需求和使用模式。根據適應症，該產品用於治療思覺失調症的急性躁動和雙相情感障礙的急性躁鬱症躁症發作，並根據嚴重程度進一步分為中度和重度。這些臨床階段會影響劑量選擇、監測強度和給藥環境偏好。根據最終用戶，該產品在醫院藥房（包括急診和精神科病房）以及專科診所（包括日間醫院和門診診所）均有供應。這些不同的環境有不同的人員配備模式、處方集和儲存方式，進而影響訂購頻率和管瓶配置偏好。

區域分析突顯了美洲、歐洲、中東和非洲以及亞太地區在注射劑採購、臨床應用和供應穩定性方面的差異。

區域趨勢對注射用齊拉西酮甲磺酸鹽的可及性、採購慣例和臨床應用模式有顯著影響。在美洲，成熟的醫院系統和一體化的供應鏈確保了可預測的處方集週期和大規模預算，但集中式的低溫運輸和無菌製造地也使其容易受到區域供應中斷的影響。該地區的臨床醫生越來越重視藥物的快速療效和可靠的安全性監測，這正在影響醫院的用藥選擇和培訓投入。

競爭考察和營運狀況分析，重點在於注射劑治療領域中創新藥廠、非專利和無菌契約製造生產商不斷變化的角色。

注射用精神科藥物市場的競爭格局由成熟的創新藥廠、非專利參與企業和專業的無菌契約製造共同構成，它們各自為供應鏈帶來不同的優勢。擁有成熟配方的成熟製藥公司在臨床醫生認可度、監管文件和完善的藥物監測系統方面保持優勢，這些優勢有助於其處方箋被納入醫院處方集。同時，非專利生產商和二線參與企業專注於成本競爭力和營運效率，通常在管瓶規格、供應可靠性和快速分銷方面競爭。

為製造商、醫院採購部門和臨床領導者提供切實可行的建議，以加強注射療法的供應韌性、最佳化利用率並降低臨床風險

製造商、醫院採購和臨床實踐領域的領導者可以採取切實可行的措施，提高注射用齊拉西酮甲磺酸鹽的可及性並最佳化其治療價值。製造商應優先考慮供應鏈的透明度和多元化，投資於替代原料藥來源以及本地無菌填充和包裝能力，以降低貿易政策變化和物流中斷的風險。此外，還應加強上市後安全計畫和臨床醫生教育，以解決影響醫療機構採用的劑量差異和心電圖監測的注意事項。

結合臨床醫生訪談、監管審查和供應鏈分析，採用穩健的混合調查方法，以產生可操作的營運洞察。

本調查方法整合了多方面的證據分析、專家諮詢和營運分析，旨在全面了解注射用齊拉西酮甲磺酸鹽的市場環境。主要研究內容包括對急診、精神科病房、日間醫院和門診的臨床醫生進行結構化訪談，以收集實際用藥實踐和安全方面的考量。這些臨床見解，以及與醫院採購負責人和無菌契約製造的討論，揭示了供應鏈動態、包裝偏好和營運限制。

綜合概述臨床應用、供應鏈韌性和策略採購，以指導未來的准入和營運規劃

總之，注射使用齊拉西酮甲磺酸鹽在急性精神疾病治療中佔有重要地位，因為這類疾病需要快速起效、安全有效且供應可靠。臨床需求源自於治療思覺失調症發作的需要，而口服給藥在這些情況下並不適用，因此對給藥方案的柔軟性、包裝選擇和監測通訊協定提出了特殊要求。同時，近期關稅政策的變化以及全球供應鏈面臨的壓力凸顯了多元化採購、區域生產能力以及製造商、醫院和契約製造之間更緊密合作的必要性。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 注射以齊拉西酮甲磺酸鹽市場依適應症分類

  • 思覺失調症急性躁動
    • 緩和
    • 嚴重
  • 雙極性情感障礙的急性躁鬱症發作
    • 緩和
    • 嚴重

9. 注射以齊拉西酮甲磺酸鹽市場（依濃度分類）

  • 20mg
  • 40mg
  • 60 mg

10. 注射用齊拉西酮甲磺酸鹽市場（依包裝類型分類）

  • 多劑量管瓶
  • 單劑量管瓶

第11章 依年齡層別分類的注射用齊拉西酮甲磺酸鹽市場

  • 成年患者
  • 老年患者

第12章 注射用齊拉西酮甲磺酸鹽市場（依最終用戶分類）

  • 醫院藥房
    • 急診室
    • 精神病房
  • 專科診所
    • 日間醫院
    • 門診部

13. 注射用齊拉西酮甲磺酸鹽市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 注射用齊拉西酮甲磺酸鹽市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國注射用齊拉西酮甲磺酸鹽市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國注射用齊拉西酮甲磺酸鹽市場

17. 中國注射用齊拉西酮甲磺酸鹽市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Aurobindo Pharma Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Jubilant Generics Limited
  • Lupin Limited
  • Mylan NV
  • Pfizer Inc.
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Zydus Cadila
Product Code: MRR-4F7A6D4FD8DA

The Ziprasidone Mesylate for Injection Market was valued at USD 1.39 billion in 2025 and is projected to grow to USD 1.51 billion in 2026, with a CAGR of 9.84%, reaching USD 2.68 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.39 billion
Estimated Year [2026] USD 1.51 billion
Forecast Year [2032] USD 2.68 billion
CAGR (%) 9.84%

Comprehensive introduction to the clinical role operational constraints and stakeholder priorities surrounding injectable ziprasidone mesylate in acute psychiatric care

The introduction outlines the therapeutic role and clinical utility of ziprasidone mesylate for injection within acute psychiatric care settings, setting a foundation for deeper operational and strategic analysis. As an intramuscular antipsychotic used to rapidly manage acute agitation in schizophrenia and acute manic episodes in bipolar disorder, this formulation fills a critical need where oral administration is impractical or ineffective due to patient agitation or risk of noncompliance. Clinicians rely on injectable options to stabilize patients, enable rapid de-escalation of behavioral emergencies, and facilitate timely transitions to longer-term oral regimens.

Beyond clinical use, injectable ziprasidone mesylate presents distinct manufacturing and logistics requirements, including aseptic production, sterility assurance, and packaging considerations that influence distribution and hospital formulary decisions. Regulatory scrutiny around cardiac safety and appropriate monitoring informs clinical protocols and training needs in emergency and psychiatric ward settings. Consequently, stakeholders across pharmacy, clinical leadership, procurement, and manufacturing must coordinate to ensure safe, reliable access while maintaining adherence to evolving safety guidelines and institutional policies.

This report's introductory analysis establishes the clinical rationale, operational constraints, and stakeholder imperatives that frame downstream sections focused on market dynamics, tariff impacts, segmentation, regional variations, competitive behavior, and action-oriented recommendations.

How clinical priorities supply chain resilience and regulatory tightening are jointly reshaping the global injectable psychiatric therapeutics environment

The landscape for injectable psychiatric treatments is undergoing transformative shifts driven by evolving clinical practice, supply chain reconfiguration, and intensified regulatory oversight. Clinicians increasingly prioritize rapid-acting, high-safety-profile interventions that minimize the need for physical restraints and reduce emergency department throughput. This clinical emphasis has elevated the strategic importance of injectable antipsychotics that offer predictable onset, manageable adverse event profiles, and compatibility with hospital monitoring protocols.

Parallel to clinical trends, supply chains are being redesigned to improve resilience against geopolitical shocks and pharmaceutical shortages. Manufacturers and health systems are investing in redundant sourcing, regional contract manufacturing, and inventory optimization to protect access to critical injectables. Regulatory bodies are tightening expectations for post-marketing surveillance and risk mitigation plans, particularly for products with known safety considerations, which requires manufacturers to invest in enhanced pharmacovigilance and clinician education.

Together, these forces are catalyzing shifts in procurement behavior, fostering closer collaboration between manufacturers and providers, and accelerating innovation in packaging, dosing flexibility, and administration protocols. These trends underscore a market environment in which operational agility, robust quality systems, and clinical evidence of safety and rapid efficacy confer competitive advantage.

Assessing the operational and procurement consequences of United States tariff measures introduced in 2025 that disrupted sterile injectable supply chains

Cumulative tariff actions implemented by the United States in 2025 have produced broad implications for the pharmaceutical supply chain, with particular relevance to sterile injectable therapies. Tariffs on imported active pharmaceutical ingredients and packaging components have increased the cost basis for manufacturers that rely on international sourcing, prompting immediate tactical responses including renegotiation of supplier contracts and short-term price adjustments. These measures have also accelerated strategic initiatives to diversify supply networks and relocate critical manufacturing steps closer to end markets.

Hospitals and specialty clinics have felt secondary effects through procurement cycles, with supply officers reassessing long-term purchasing agreements and inventory policies to mitigate exposure to ongoing tariff volatility. In response, manufacturers have prioritized transparency with institutional purchasers, sharing supply risk assessments and collaborating on buffer stock strategies. Regulatory timelines have occasionally been impacted where component substitutions or manufacturing site changes require additional validation, lengthening lead times for certain batches.

Importantly, tariff-driven cost pressures are not uniform across all participants. Firms with vertically integrated manufacturing and established domestic sterile production capacity have been better positioned to absorb incremental costs, whereas pure contract manufacturers dependent on imported raw materials have faced tighter margins. As a result, expect continued emphasis on supply chain mapping, regionalization of production, and contractual safeguards to stabilize access to injectable ziprasidone mesylate amid persistent trade policy uncertainty.

In-depth segmentation analysis revealing how clinical severity end-user setting formulation strength packaging and age group considerations interact to determine product use

Segmentation analysis clarifies how clinical, procurement, and formulation variables intersect to shape demand and usage patterns for injectable ziprasidone mesylate. Based on indication, the product is used for acute agitation in schizophrenia and acute manic episodes in bipolar disorder, each of which is further differentiated by severity into moderate and severe presentations; these clinical gradations influence dosing choices, monitoring intensity, and administration setting preferences. Based on end user, the product serves hospital pharmacy environments including the emergency department and psychiatric ward, as well as specialty clinic contexts that encompass day hospitals and outpatient clinics; these distinct settings have different staffing models, formularies, and storage practices that affect ordering cadence and vial configuration preferences.

Based on strength, the injectable portfolio includes 20 mg, 40 mg, and 60 mg options, enabling clinicians to tailor doses to patient severity and tolerability while facilitating step-down strategies in acute care pathways. Based on packaging, available formats include multi-dose vials and single-dose vials, with multi-dose vials offering inventory efficiencies for higher-volume hospital wards and single-dose vials reducing cross-contamination risk in lower-volume clinics. Based on age group, the product is deployed across adult and geriatric patients, where geriatric use prompts additional safety considerations, dose adjustments, and monitoring for comorbidities.

Taken together, these segmentation lenses reveal that commercial and clinical strategies must be finely tuned to the interplay of indication severity, administration setting, strength availability, packaging choice, and patient age to ensure optimal therapeutic and operational outcomes.

Regional landscape analysis demonstrating how Americas Europe Middle East Africa and Asia-Pacific differ in procurement clinical adoption and supply resilience for injectables

Regional dynamics materially influence access, procurement practices, and clinical adoption patterns for injectable ziprasidone mesylate. In the Americas, established hospital systems and integrated supply chains favor predictable procurement cycles and larger formulary budgets, yet the region also contends with concentrated cold chain and sterile manufacturing hubs that create vulnerability to localized disruptions. Clinicians in this region increasingly demand evidence of rapid efficacy and robust safety monitoring, which shapes hospital adoption and training investments.

In Europe, the Middle East & Africa, variability in public procurement mechanisms, regulatory harmonization, and healthcare infrastructure results in heterogeneous access. Some countries operate centralized tender systems that prioritize cost-effectiveness and long-term supply agreements, while others rely on decentralized procurement that amplifies variability in vial format preference and strength availability. The region's diverse clinical guidelines and differing levels of acute psychiatric service capacity create a complex landscape for manufacturers seeking to align distribution and support services.

In Asia-Pacific, rapid healthcare modernization and investment in emergency and mental health services are expanding demand for acute injectable therapies, but reliance on global API and packaging supply chains makes the region sensitive to tariff shifts and logistical constraints. Local contract manufacturing growth and regional regulatory maturation offer pathways to improve supply resilience and to tailor packaging and dosing options to the needs of high-volume hospital systems and community-based clinics.

Across all regions, stakeholder collaboration, regional manufacturing investments, and tailored clinical support programs are critical to ensuring consistent access and appropriate usage of injectable ziprasidone mesylate.

Competitive and operational company insights highlighting the evolving roles of innovators generics and sterile contract manufacturers in injectable therapeutics

Competitive dynamics in the injectable psychiatric therapeutics space are shaped by legacy innovators, generic entrants, and specialized sterile contract manufacturers, each bringing distinct capabilities to the supply chain. Established pharmaceutical firms with proven formulations retain advantages in clinician familiarity, regulatory dossiers, and established pharmacovigilance systems, which supports hospital formulary inclusion. Meanwhile, generic manufacturers and secondary entrants focus on cost competitiveness and operational efficiencies, often competing on vial formats, supply reliability, and responsive distribution.

Contract manufacturing organizations that specialize in aseptic fill-finish operations play an increasingly pivotal role, enabling brand owners to scale production without the capital burden of expanding sterile manufacturing capacity. These providers also support rapid qualification of alternative packaging and vial sizes to match end-user needs. Strategic partnerships between product owners and large hospital systems or group purchasing organizations are becoming more common, aligning production planning with predictable demand streams and enabling joint investments in safety training and inventory management solutions.

Innovation efforts center on improving dosing flexibility, simplifying administration protocols, and strengthening post-market safety surveillance. Companies that can combine clinical support services, reliable aseptic manufacturing, and transparent supply chain risk communication will be best positioned to meet institutional purchasers' expectations and secure long-term placement in acute care formularies.

Practical recommendations for manufacturers hospital procurement and clinical leaders to strengthen supply resilience optimize utilization and reduce clinical risk for injectable therapies

Leaders across manufacturing, hospital procurement, and clinical practice can take specific, actionable steps to fortify access and optimize the therapeutic value of injectable ziprasidone mesylate. Manufacturers should prioritize supply chain visibility and diversification, investing in alternate API sources and regional aseptic fill-finish capacity to reduce vulnerability to trade policy changes and logistical disruptions. They should also strengthen post-marketing safety programs and clinician education to address dosing nuances and cardiac monitoring considerations that influence institutional adoption.

Hospital and clinic leaders should incorporate scenario-based procurement planning that balances inventory resilience with shelf-life considerations and storage constraints. Procurement teams ought to negotiate contractual clauses that promote supply continuity, such as dual-sourcing agreements and prioritized allocation commitments. Clinicians and pharmacy leaders should collaborate to standardize administration protocols across emergency departments, psychiatric wards, day hospitals, and outpatient clinics, thereby reducing variability in patient handling and improving safety outcomes.

Across the ecosystem, stakeholders should pursue collaborative pilots that test alternative vial formats, dosing algorithms, and remote monitoring tools to minimize adverse events and streamline transitions from acute injectable treatment to oral maintenance therapy. These approaches will reduce clinical risk, improve patient throughput, and strengthen institutional readiness for future supply chain shocks.

Robust mixed-methods research approach combining clinician interviews regulatory review and supply chain analysis to generate actionable operational insights

The research methodology combines a multi-source evidence approach with expert consultation and operational analysis to produce a comprehensive view of the injectable ziprasidone mesylate environment. Primary inputs include structured interviews with clinicians across emergency departments, psychiatric wards, day hospitals, and outpatient clinics to capture real-world administration practices and safety concerns. These clinical insights were complemented by discussions with hospital procurement professionals and sterile contract manufacturers to map supply chain dynamics, packaging preferences, and operational constraints.

Secondary research encompassed regulatory guidance, safety advisories, and peer-reviewed clinical literature to ensure accuracy on indication-specific use, dosing standards, and monitoring recommendations. Supply chain and trade policy analysis integrated customs and tariff announcements, industry reports on sterile manufacturing capacity, and public filings to assess the implications of recent tariff actions. The methodology emphasized triangulation across sources to validate findings and to surface practical strategies that stakeholders can implement.

Limitations include variability in regional procurement practices and the evolving nature of trade policy, which may alter the operational landscape over time. To address this, the methodology incorporated sensitivity checks and sought expert validation to ensure robustness of directional insights and operational recommendations.

Concluding synthesis tying clinical use supply chain resilience and strategic procurement together to guide future access and operational planning

In conclusion, injectable ziprasidone mesylate occupies a critical niche in acute psychiatric care where rapid efficacy, safety management, and supply reliability converge. Clinical demand stems from the need to manage acute agitation in schizophrenia and manic episodes in bipolar disorder when oral routes are not viable, and this creates specific requirements around dosing flexibility, packaging options, and monitoring protocols. Simultaneously, recent tariff developments and global supply chain pressures have highlighted the need for diversified sourcing, regional manufacturing capacity, and closer coordination between manufacturers, hospitals, and contract manufacturers.

Strategic responses that combine enhanced pharmacovigilance, targeted clinician education, and investment in sterile manufacturing resilience will help secure access and maintain high standards of patient care. Procurement strategies that emphasize contractual protections, inventory optimization, and cross-stakeholder pilots can mitigate short-term disruptions while supporting longer-term system improvements. Ultimately, organizations that adopt an integrated approach-aligning clinical, operational, and commercial priorities-will be best positioned to deliver safe, timely, and cost-effective acute psychiatric care using injectable ziprasidone mesylate.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Ziprasidone Mesylate for Injection Market, by Indication

  • 8.1. Acute Agitation In Schizophrenia
    • 8.1.1. Moderate
    • 8.1.2. Severe
  • 8.2. Acute Manic Episodes In Bipolar Disorder
    • 8.2.1. Moderate
    • 8.2.2. Severe

9. Ziprasidone Mesylate for Injection Market, by Strength

  • 9.1. 20 Mg
  • 9.2. 40 Mg
  • 9.3. 60 Mg

10. Ziprasidone Mesylate for Injection Market, by Packaging

  • 10.1. Multi-Dose Vial
  • 10.2. Single-Dose Vial

11. Ziprasidone Mesylate for Injection Market, by Age Group

  • 11.1. Adult Patients
  • 11.2. Geriatric Patients

12. Ziprasidone Mesylate for Injection Market, by End User

  • 12.1. Hospital Pharmacy
    • 12.1.1. Emergency Department
    • 12.1.2. Psychiatric Ward
  • 12.2. Specialty Clinic
    • 12.2.1. Day Hospital
    • 12.2.2. Outpatient Clinic

13. Ziprasidone Mesylate for Injection Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Ziprasidone Mesylate for Injection Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Ziprasidone Mesylate for Injection Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Ziprasidone Mesylate for Injection Market

17. China Ziprasidone Mesylate for Injection Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Aurobindo Pharma Limited
  • 18.6. Cipla Limited
  • 18.7. Dr. Reddy's Laboratories Ltd.
  • 18.8. Glenmark Pharmaceuticals Ltd.
  • 18.9. Jubilant Generics Limited
  • 18.10. Lupin Limited
  • 18.11. Mylan N.V.
  • 18.12. Pfizer Inc.
  • 18.13. Sandoz International GmbH
  • 18.14. Sun Pharmaceutical Industries Ltd.
  • 18.15. Teva Pharmaceutical Industries Ltd.
  • 18.16. Torrent Pharmaceuticals Ltd.
  • 18.17. Zydus Cadila

LIST OF FIGURES

  • FIGURE 1. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY STRENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY PACKAGING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE AGITATION IN SCHIZOPHRENIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE AGITATION IN SCHIZOPHRENIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE AGITATION IN SCHIZOPHRENIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE AGITATION IN SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY MODERATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY MODERATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SEVERE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SEVERE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE MANIC EPISODES IN BIPOLAR DISORDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE MANIC EPISODES IN BIPOLAR DISORDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE MANIC EPISODES IN BIPOLAR DISORDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE MANIC EPISODES IN BIPOLAR DISORDER, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY MODERATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY MODERATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SEVERE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SEVERE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY 20 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY 20 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY 20 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY 40 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY 40 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY 40 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY 60 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY 60 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY 60 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY MULTI-DOSE VIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY MULTI-DOSE VIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY MULTI-DOSE VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SINGLE-DOSE VIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SINGLE-DOSE VIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SINGLE-DOSE VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY GERIATRIC PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY GERIATRIC PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY EMERGENCY DEPARTMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY EMERGENCY DEPARTMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY EMERGENCY DEPARTMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY PSYCHIATRIC WARD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY PSYCHIATRIC WARD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY PSYCHIATRIC WARD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY DAY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY DAY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY DAY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY OUTPATIENT CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY OUTPATIENT CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY OUTPATIENT CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE AGITATION IN SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE MANIC EPISODES IN BIPOLAR DISORDER, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE AGITATION IN SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE MANIC EPISODES IN BIPOLAR DISORDER, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE AGITATION IN SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE MANIC EPISODES IN BIPOLAR DISORDER, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE AGITATION IN SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE MANIC EPISODES IN BIPOLAR DISORDER, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE AGITATION IN SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE MANIC EPISODES IN BIPOLAR DISORDER, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE AGITATION IN SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE MANIC EPISODES IN BIPOLAR DISORDER, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE AGITATION IN SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE MANIC EPISODES IN BIPOLAR DISORDER, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE AGITATION IN SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE MANIC EPISODES IN BIPOLAR DISORDER, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE AGITATION IN SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE MANIC EPISODES IN BIPOLAR DISORDER, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 160. GCC ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GCC ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 162. GCC ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE AGITATION IN SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 163. GCC ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE MANIC EPISODES IN BIPOLAR DISORDER, 2018-2032 (USD MILLION)
  • TABLE 164. GCC ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 165. GCC ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 166. GCC ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. GCC ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. GCC ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 169. GCC ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE AGITATION IN SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE MANIC EPISODES IN BIPOLAR DISORDER, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE AGITATION IN SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE MANIC EPISODES IN BIPOLAR DISORDER, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 190. G7 ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. G7 ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 192. G7 ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE AGITATION IN SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 193. G7 ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE MANIC EPISODES IN BIPOLAR DISORDER, 2018-2032 (USD MILLION)
  • TABLE 194. G7 ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 195. G7 ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 196. G7 ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. G7 ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. G7 ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 199. G7 ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 200. NATO ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. NATO ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 202. NATO ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE AGITATION IN SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 203. NATO ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE MANIC EPISODES IN BIPOLAR DISORDER, 2018-2032 (USD MILLION)
  • TABLE 204. NATO ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 205. NATO ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 206. NATO ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. NATO ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. NATO ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 209. NATO ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE AGITATION IN SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE MANIC EPISODES IN BIPOLAR DISORDER, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE AGITATION IN SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY ACUTE MANIC EPISODES IN BIPOLAR DISORDER, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA ZIPRASIDONE MESYLATE FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)